Orthofix Medical Inc. (NASDAQ:OFIX) CFO Julie Andrews Sells 4,655 Shares

Orthofix Medical Inc. (NASDAQ:OFIX) CFO Julie Andrews sold 4,655 shares of the business’s stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $17.89, for a total value of $83,277.95. Following the completion of the transaction, the chief financial officer now directly owns 28,312 shares of the company’s stock, valued at $506,501.68. The trade was a 14.12 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

Orthofix Medical Trading Down 0.5 %

Shares of NASDAQ:OFIX opened at $18.28 on Friday. The firm has a market capitalization of $698.48 million, a price-to-earnings ratio of -5.84 and a beta of 1.10. The business’s 50 day moving average price is $18.08 and its 200-day moving average price is $16.94. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.39 and a quick ratio of 1.11. Orthofix Medical Inc. has a 1 year low of $12.08 and a 1 year high of $20.73.

Orthofix Medical (NASDAQ:OFIX) last announced its earnings results on Thursday, November 7th. The medical device company reported ($0.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.57). Orthofix Medical had a negative net margin of 15.18% and a negative return on equity of 21.25%. The company had revenue of $196.61 million during the quarter, compared to analyst estimates of $196.60 million. During the same quarter last year, the business earned ($0.77) EPS. On average, equities research analysts forecast that Orthofix Medical Inc. will post -2.81 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts recently issued reports on OFIX shares. Canaccord Genuity Group assumed coverage on shares of Orthofix Medical in a research note on Wednesday. They issued a “buy” rating and a $24.00 target price for the company. Stifel Nicolaus upgraded shares of Orthofix Medical from a “hold” rating to a “buy” rating and upped their price objective for the stock from $18.00 to $24.00 in a research report on Friday, November 8th. Finally, Roth Mkm reissued a “buy” rating and set a $22.00 target price (up from $20.00) on shares of Orthofix Medical in a research note on Friday, November 8th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $23.33.

Hedge Funds Weigh In On Orthofix Medical

A number of hedge funds have recently made changes to their positions in OFIX. R Squared Ltd acquired a new stake in shares of Orthofix Medical in the fourth quarter worth approximately $50,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Orthofix Medical by 5.9% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,994 shares of the medical device company’s stock worth $156,000 after purchasing an additional 559 shares during the last quarter. XTX Topco Ltd purchased a new stake in shares of Orthofix Medical during the second quarter worth $175,000. Assenagon Asset Management S.A. acquired a new stake in shares of Orthofix Medical in the third quarter valued at about $216,000. Finally, Quest Partners LLC lifted its stake in shares of Orthofix Medical by 187.1% in the third quarter. Quest Partners LLC now owns 13,908 shares of the medical device company’s stock worth $217,000 after buying an additional 9,063 shares in the last quarter. Institutional investors and hedge funds own 89.76% of the company’s stock.

About Orthofix Medical

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.